Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Future Market Size Estimation For The Adeno-Associated Viral Vectors Market Covering 2025–2034?
The adeno-associated viral vectors market has seen a rapid expansion in its size over recent years. It is anticipated to expand from $2.69 billion in 2024 to $3.17 billion in 2025, achieving a compound annual growth rate (CAGR) of 17.6%. The historical growth of this market is attributable to developments in vaccines, a boost in funding and investment, partnerships between academic institutions and industry, the widening scope of clinical trials, and greater public awareness and advocacy.
The adeno-associated viral vectors market is projected to experience substantial expansion in the coming years. This market is forecast to reach $5.85 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 16.6%. Key drivers for this growth during the projected period include the broadening scope of therapeutic applications, the rising incidence of both genetic and neurological disorders, favorable regulatory approvals and backing, and reductions in production costs. Significant trends anticipated in the forecast period encompass progress in gene therapy, new technological breakthroughs, the development of scalable manufacturing methods, increased collaborations and investments, and further technological strides.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp
Which Drivers Are Impacting The Adeno-Associated Viral Vectors Market?
The growing occurrence of genetic conditions is anticipated to fuel the expansion of the adeno-associated viral vectors market in the future. These disorders stem from irregularities in an individual’s DNA, resulting in either physical or developmental impairments. Enhancements in diagnostic methods, increased public understanding, and a later reproductive age, combined with environmental influences and genetic drift, contribute to the escalating frequency of genetic disorders. In gene therapy for genetic disorders, adeno-associated viral vectors are employed to introduce corrective genes into specific cells, offering potential treatments for conditions such as muscular dystrophy or cystic fibrosis. As an illustration, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations dedicated to international public health, reported in February 2023 that approximately 240,000 infant fatalities worldwide within the first 28 days of life annually were due to congenital diseases. Furthermore, congenital diseases account for the deaths of another 170,000 children aged 1 month to 5 years. Consequently, the rising incidence of genetic disorders is propelling the adeno-associated viral vectors market.
What Are The Major Segments Identified In The Adeno-Associated Viral Vectors Market?
The adeno-associated viral vectorsmarket covered in this report is segmented –
1) By Type Of Therapy: Gene Augmentation; Immunotherapy; Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo; In Vivo
3) By Target Therapeutic Area: Genetic Disorders; Hematological Disorders; Infectious Diseases; Metabolic Disorders; Ophthalmic Disorders; Muscle Disorders; Neurological Disorders; Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical; Clinical; Commercial
5) By Application Area: Gene Therapy; Cell Therapy; Vaccines
Subsegments:
1) By Gene Augmentation: Inherited Genetic Disorders; Muscular Dystrophy; Cystic Fibrosis; Hemophilia
2) By Immunotherapy: Cancer Immunotherapy; Viral Infections Immunotherapy; Autoimmune Diseases Immunotherapy
3) By Other Types Of Therapies: Gene Editing; RNA Therapy; Antiviral Therapy
What Trends Are Redefining The Adeno-Associated Viral Vectors Market Dynamics?
Major companies operating in the adeno-associated viral vectors market are focusing on offering off-the-shelf availability of replication-capsid plasmids to gain a competitive edge. Rep/Cap plasmids, commonly utilized in gene therapy for adeno-associated virus (AAV) vector production, are readily available from numerous commercial suppliers catering to molecular biology research needs. For instance, in January 2024, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced an off-the-shelf replication-capsid plasmid range that streamlines AAV-based gene therapy initiatives. This expansion of their product portfolio complements existing lentiviral packaging and AAV Helper plasmid offerings, cutting manufacturing efforts by as much as 66%. These ready-to-use plasmids undergo batch production with meticulous documentation, adhering to CMC guidelines and accompanied by a Certification of Analysis (COA) to facilitate IND and Clinical Trial Application (CTA) submissions.
Who Are The Key Multinational Companies Dominating The Adeno-Associated Viral Vectors Market?
Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Adeno-Associated Viral Vectors Market Outlook?
North America was the largest region in the adeno-associated viral vectors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Adeno-Associated Viral Vectors Market Report:
https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp
Browse Through More Reports Similar to the Global Adeno-Associated Viral Vectors Market 2025, By The Business Research Company
Viral Vectors And Plasmid Dna Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Bacterial And Plasmid Vector Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report
Adenosine Triphosphate Atp Assays Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model